Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 4, 2000, Pages

  Plouffe, J F ^a  

^a N 1135 Doan Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; EVERNIMICIN; LINEZOLID; MACROLIDE; METICILLIN; ORITAVANCIN; OXACILLIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DIARRHEA; HAEMOPHILUS INFLUENZAE; HEADACHE AND FACIAL PAIN; HUMAN; MYCOPLASMA PNEUMONIAE; NAUSEA; PENICILLIN RESISTANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL;

EID: 0034455849     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314080     Document Type: Review

References (52)

1. Therapy for pneumococcal infection at the millennium: Doubts and certainties
2. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
3. Multiple antibiotic resistance in Streptococcus pneumoniae
4. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991
5. Resistance to antimicrobial chemotherapy: A prescription for research and action
6. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia
7. Community-acquired pneumonia: Definition, epidemiology, and outcome
8. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study
9. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program
10. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds
11. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander project 1992-1996
12. Bird's eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device-days
13. National Nosocomial Infections Surveillance System. Nosocomial infections in medical intensive care units in the United States
14. Nosocomial bloodstream infections in United States hospitals: A 3-year analysis
15. An overview of nosocomial infections, including the role of the microbiology laboratory
16. Emergence of hetero-VRSA strains in Japanese hospitals and its countermeasure
17. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin
18. Emergence of vancomycin resistance in Staphylococcus aureus
19. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
20. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
21. Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
22. Gram-positive resistance: Challenge for the development of new antibiotics
23. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
24. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
25. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
26. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
27. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
28. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
29. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766, two novel fluorinated oxazolidinones
30. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
31. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
32. Comparative in vitro activity and postantibiotic effect of oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus faecium
33. Linezolid, critical characteristics
34. Linezolid
35. Oxazolidinones
36. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates
37. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
38. Comparative activity of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates originating from 20 European university hospitals
39. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci
40. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
41. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
42. Oral linezolid in the treatment of community-acquired pneumonia: A phase III trial
43. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized community-acquired pneumonia
44. Linezolid is superior to cephalosporins in the treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia
45. Linezolid is equivalent to vancomycin in the treatment of patients with gram-positive nosocomial pneumonia
46. Comparison of oral linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase III trial
47. Comparison of linezolid to oxacillin followed by oral dicloxacillin in the treatment of complicated skin infections: Results from a multinational phase III trial
48. Randomized comparison of linezolid (PNU-100766) versus oxacillin/dicloxacillin for the treatment of complicated skin and soft tissue infections